|
RAF1 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 5.92059999915406E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.09040000001648E-06 |
| Normal-vs-Stage2 |
4.841000E-04 |
| Normal-vs-Stage3 |
5.54180001888227E-09 |
| Normal-vs-Stage4 |
2.35979999985148E-07 |
| Stage1-vs-Stage2 |
7.616000E-01 |
| Stage1-vs-Stage3 |
6.002300E-03 |
| Stage1-vs-Stage4 |
1.411180E-01 |
| Stage2-vs-Stage3 |
1.412790E-01 |
| Stage2-vs-Stage4 |
4.825400E-01 |
| Stage3-vs-Stage4 |
3.572200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.56809999984908E-07 |
| Normal-vs-AfricanAmerican |
9.063400E-03 |
| Normal-vs-Asian |
1.974390E-04 |
| Caucasian-vs-AfricanAmerican |
3.791400E-01 |
| Caucasian-vs-Asian |
9.669700E-02 |
| AfricanAmerican-vs-Asian |
9.968800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.60829999998435E-06 |
| Normal-vs-Female |
6.84330000444433E-08 |
| Male-vs-Female |
6.545800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.05449999999274E-05 |
| Normal-vs-Age(41-60Yrs) |
6.88610002352874E-09 |
| Normal-vs-Age(61-80Yrs) |
6.21139999990028E-07 |
| Normal-vs-Age(81-100Yrs) |
1.233520E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.226500E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.117180E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.475200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.873000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.002000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.723600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.838300E-04 |
| Classical-VS-Follicular |
7.307600E-01 |
| Classical-VS-Other |
6.103400E-01 |
| Classical-VS-Normal |
1.24180000005136E-06 |
| Tall-VS-Follicular |
1.416390E-02 |
| Tall-VS-Other |
2.611600E-02 |
| Tall-VS-Normal |
8.3789000182577E-09 |
| Follicular-VS-Other |
5.931400E-01 |
| Follicular-VS-Normal |
1.191430E-04 |
| Other-VS-Normal |
1.382580E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.37779999964671E-07 |
| Normal-vs-N1 |
4.23589999742902E-08 |
| N0-vs-N1 |
1.618810E-01 |
|
|
